Central nervous system relapse in a pediatric anaplastic large cell lymphoma patient with CLTC/ALK translocation treated with alectinib: A case report

Figure 5 The sample at the diagnosis time-point showing the expected 270 bp CLTC-ALK reverse transcription-polymerase chain reaction product (three bands represent three repetitions) (A) and direct sequencing results of polymerase chain reaction products (B). The arrow shows the translocation breakpoint (B).